|Stage of funding:||Current|
|Therapeutic group:||Infectious Diseases|
Founded by a highly experienced management team, Atea Pharmaceuticals, Inc. is an emerging biopharmaceutical company which is engaged in the acquisition, discovery and development of novel antiviral therapeutics.
Clearside Biomedical, Inc. (Nasdaq:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced completion of enrollment of an exploratory clinical trial (the “HULK” trial) of CLS-TA for suprachoroidal administration, its proprietary suspension formulation of the corticosteroid triamcinolone acetonide, with or without intravitreal Eylea® (aflibercept), for the treatment of diabetic macular edema (“DME”).
19 April 2017
11 April 2017
10 April 2017